UTILISATION DE MÉTABOLITES DU MICROBIOTE POUR DIFFÉRENCIER DES LYMPHOCYTES T NAÏFS ET PROCÉDÉS ASSOCIÉS D'INDUCTION OU DE PRÉVENTION DES AFFECTIONS INFLAMMATOIRES

摘要

This disclosure relates to methods and compositions for addressing conditions of dysbiosis and/or inflammation, such as enteropathy, associated with administration of non-steroidal anti-inflammatory drug (NSAID). The disclosure includes methods comprising administering an effective amount of a tryptophan derived microbiota metabolite (TDMM) to a subject that has also been administered, or is expected to have administered, a NSAID.